Key result
Atorvastatin 10 mg/day significantly reduced total cholesterol by 23% (P<0.001) at 36 months in severe CKD patients, though 21% discontinued therapy due to adverse effects.
Why the study?
Does atorvastatin 10 mg/day improve lipid profiles in patients with severe chronic kidney disease (stages 4 and 5)?
Population
143 patients with chronic kidney disease (CKD) stages 4 and 5 and a glomerular filtration rate of <30 ml/min
Comparison
Atorvastatin 10 mg once daily vs Control group
Design
RCT, randomized, open
Follow-up
mean 20+/-14.4 months for atorvastatin, 22+/-12.7 months…
Authors
Loading...
Demonstrates lipid-lowering efficacy in severe CKD but requires close monitoring for tolerability.
RCT (n=143)
Open-label
randomized
Does atorvastatin 10 mg/day improve lipid profiles in patients with severe chronic kidney disease (stages 4 and 5)?
Effect estimate: -23% reduction in total cholesterol vs baseline
p-value: p=<0.001
Atorvastatin 10 mg/day effectively lowers LDL cholesterol in severe CKD patients, but is associated with a 21% discontinuation rate due to side effects like gastrointestinal discomfort and headache.
Holmberg et al. (2005) conducted an RCT in chronic kidney disease (CKD) stages 4 and 5 (n=143). Atorvastatin vs. Control was evaluated on Total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride levels (-23% reduction in total cholesterol vs baseline, p=<0.001). Atorvastatin 10 mg/day significantly reduced total cholesterol by 23% (P<0.001) at 36 months in severe CKD patients, though 21% discontinued therapy due to adverse effects.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: